Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,331 across all filing types
Latest filing 2018-07-16 Environmental & Social …
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
New publication shows that 91% of patients would recommend Blue Light Cystoscopy with Cysview
Environmental & Social Information Classification · 99% confidence The document text is extremely short (227 characters) and contains a headline about a publication's findings, followed immediately by the instruction 'See attachement on www.newsweb.no'. This strongly indicates that the document itself is not the full report or publication, but rather an announcement that the report/information has been made available elsewhere. Given the context of a brief announcement pointing to an attachment or external link, the most appropriate classification is Report Publication Announcement (RPA), as it announces the publication of information, or RNS if RPA is too specific, but RPA fits better as it relates to a 'publication'. Since the content is a brief announcement about a publication, RPA is selected.
2018-07-16 English
Photocure ASA: Share capital increase registered
Share Issue/Capital Change Classification · 98% confidence The document explicitly states that a 'Share capital increase as part of the employee long-term incentive program... has been registered'. It details the resulting share capital and the number of shares. This directly relates to a change in the company's capital structure or share issuance, which aligns best with the 'Share Issue/Capital Change' definition (SHA). Although it is a short announcement, the core subject matter is a capital change, not just the announcement of a report.
2018-07-11 English
Photocure ASA: Kjetil Hestdal steps down as CEO
Board/Management Information Classification · 100% confidence The document explicitly announces that the President and Chief Executive Officer, Kjetil Hestdal, is stepping down and that the CFO is appointed as interim CEO. This directly relates to a change in senior management. Based on the provided definitions, this falls under 'Board/Management Information' (Code: MANG). The document is a formal announcement, not a comprehensive report or a general regulatory filing fallback.
2018-06-26 English
Photocure ASA: Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document explicitly states it is a 'Mandatory notification of trade' concerning the Chairperson of the Board (a primary insider) purchasing shares. This directly corresponds to the definition of Director's Dealing (insider trades) as per the provided categories. The filing type code for Director's Dealing is DIRS.
2018-06-07 English
Photocure: Positive results from BLC with Cysview® registry published in the Urologic Oncology Journal
Report Publication Announcement Classification · 95% confidence The document is a press release from Photocure ASA dated May 31, 2018, announcing that positive results from a clinical registry study (BLC with Cysview®) were published online in the Urologic Oncology Journal. The text focuses on announcing the publication of scientific data and providing context/links to the publication and abstract, rather than being the full financial report (10-K, IR) or a general regulatory filing (RNS). Since it is an announcement about the publication of results/data, it fits best under the category of a general announcement or a report publication announcement. Given the options, 'Report Publication Announcement' (RPA) is the most precise fit because the core action being communicated is the publication of study results in a journal, which is a form of report dissemination. It is not a standard financial earnings release (ER) or a comprehensive interim report (IR).
2018-05-31 English
Photocure ASA: Results for the first quarter of 2018
Investor Presentation Classification · 95% confidence The document is titled "RESULTS FOR FIRST QUARTER 2018" and contains key financial highlights (revenue growth, unit sales) and strategic updates for Q1 2018. This structure strongly suggests an Earnings Release (ER) or an Interim Report (IR). However, the document is presented as a 'Presentation' (indicated by the structure and the presence of CEO/CFO names followed by slides/sections) and includes detailed strategic points and FDA approval news, which often accompanies or is part of a broader Investor Presentation (IP) or a detailed Earnings Release package. Given the focus on 'Results for First Quarter 2018' and the inclusion of financial metrics, it is primarily an earnings-related document. Since it is a presentation format summarizing the period's results, 'Investor Presentation' (IP) is a strong candidate, but 'Earnings Release' (ER) covers the initial announcement of periodical financial results. The text is extensive and detailed, suggesting more than just a brief highlights release, leaning towards an Investor Presentation which often accompanies the ER. However, the primary header is 'RESULTS FOR FIRST QUARTER 2018', which aligns best with the content of an Earnings Release (ER) or an Interim Report (IR). Since it is a quarterly report summary, and the content is detailed enough to be a presentation, I will classify it as an Investor Presentation (IP) as it is structured like one, detailing strategy and results in a slide-deck format, which is common for investor briefings accompanying earnings. Revisiting the definitions: ER is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. IR is 'Comprehensive financial report for a period shorter than a year'. IP is 'Detailed presentation for investors focusing on financials, strategy, and market position'. This document fits the IP description very well due to its presentation format and strategic depth, even though it covers quarterly results. I will select IP.
2018-05-23 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.